TER — Teradyne, Inc.

Wall Street remains constructive: 19 Buy ratings vs 12 Holds, no Sells, and a consensus target of $461.50 (~24% upside). The bull case is AI/accelerator test intensity plus memory recovery; the main caution is valuation, highlighted by Baird's downgrade to Neutral on valuation after the rally.

Revenue was roughly flat-to-slow through 2023-2024 ($600-750M per quarter), then inflected sharply: Q3 2025 $769M, Q4 2025 $1,083M, Q1 2026 $1,282M, Q2 2026 $1,329M. YoY growth went from modest to +87% in Q1 2026 and +104% in Q2 2026. Operating margin expanded from 13.9% in Q2 2025 to 32.9% in Q2 2026; diluted EPS jumped from $0.49 to $2.38. This is a genuine upward inflection driven by AI compute and memory, not a one-quarter blip, though the sequential EPS easing from $2.53 to $2.38 in Q2 is normal lumpiness after a massive ramp.

Expensive versus its own history. As of 2026-08-27, TTM P/E is ~50.8x and P/S ~13.0x versus 5-year averages of ~35.1x and ~6.9x. On consensus FY EPS of $9.207, the forward P/E is ~40.4x. The PEG of 0.33 is an artifact of hyper-growth; using a more normal forward growth rate of ~25%, the stock is closer to 1.6x PEG. The strength of margins and balance sheet supports a premium, but not a cheap price.

The market has already priced in high execution: at $372, you are paying ~40x estimated forward EPS and ~51x trailing EPS. If Teradyne hits the $9.50-$11.00 long-term EPS model, the current price is approximately fair to modestly undervalued; if orders slip or AI capex pauses, a reversion toward the 35x historical average would put the stock near $320-330 on 2026 estimates. The stock is a pay-up-for-quality situation, where the risk/reward depends on continued order conversion rather than a margin of safety.

As of 2026-08-27, RSI was 48.04, neutral—not oversold or overbought. Price was 3.61% below its 20-day SMA and 2.81% below its 50-day SMA, but still 19.58% above its 200-day SMA. That describes a healthy long-term uptrend that has cooled into consolidation, not a breakdown. For timing, waiting for a reclaim of the 50-day or a test of the 200-day area would be more favorable than chasing here.

• AI hardware capex and advanced packaging (chiplets, HBM, co-packaged optics) are structurally increasing test content per device.
• Semiconductor equipment spending is inherently cyclical; non-AI segments like auto and industrial are softer under high interest rates.
• The memory recovery, with strong orders from partners like Micron, is adding a second growth engine beyond AI compute.
• Elevated interest rates make high-multiple tech names sensitive to multiple compression; TER has a beta of ~1.8.
• Longer-term semiconductor industry TAM expansion toward $3T by 2030 supports Teradyne's $6B revenue target.

• Quarterly order conversion and billings from hyperscaler AI and memory customers.
• Progress toward the stated long-term model of ~$6B revenue and $9.50-$11.00 non-GAAP EPS.
• Robotics/physical AI optionality through Universal Robots and the UR AI Trainer.
• Continued share gains in SoC test, with compute now roughly half of the test revenue mix.

• Valuation risk: at ~40-51x earnings, any revenue miss or AI order digestion could cause sharp multiple compression.
• Order lumpiness and customer concentration with a small set of hyperscaler/memory customers.
• Semiconductor cyclicality: if memory or non-AI demand disappoints, the current growth rate is unlikely to persist.
• Competitive and technology risk in high-end test, though Teradyne retains ~50% share in VIP compute test.

Teradyne is a high-quality AI infrastructure enabler with explosive growth, expanding margins, and a nearly debt-free balance sheet. The stock is not cheap, so the risk/reward is okay rather than exceptional: it is a strong business where the market has paid for much of the upside, making it a cautious buy on weakness rather than an aggressive chase at $372. This is analysis, not personalized financial advice.

I applied a 43x forward P/E to consensus FY EPS of $9.207, yielding $396.00. The 43x multiple is a premium to the 5-year average of ~35x, justified by ~25% forward EPS growth, 30%+ operating margins, ROIC near 18%, and a zero-debt balance sheet, but it is a discount to the current 50.8x trailing P/E and to the $461.50 analyst consensus target.